A "momentous" medication used to treat Alzheimer's disease was prescribed to a man in Kent, and his wife claims it has given the couple "hope.".
Around seven years ago, David Essam, 78, of Sevenoaks, began to experience symptoms of Alzheimer's.
A new drug called Lecanemab was prescribed to him as part of an international study for people with early-stage Alzheimer's disease.
He had to stop working as a joiner because he could no longer remember how to use his tools due to his Alzheimer's.
He now wears a digital watch because he is unable to read a clock face.
After three years on the trial, Cheryl Essam claimed that her husband had "deteriorated.".
However, she added that there are still things he can do, saying that the trial "has helped us" and "has given us hope.".
She said, "We're convinced that every day that David is still able to do those things is because we were fortunate enough to be on the trial.
Lecanemab combats the beta amyloid, a sticky gunge that forms in the brains of those suffering from Alzheimer's disease, and works in the early stages of the illness.
1,795 volunteers with early-stage Alzheimer's participated in the extensive international trial. Lecanemab was infused once every two weeks.
The scientific discovery was "momentous," according to Alzheimer's Research UK.
According to Ms. Essam, the trial's administrators claim to be able to demonstrate that her husband's beta amyloid levels have decreased.
There are many things I used to be able to do that I can no longer do, according to Mr. Essam. I long for that.
. "
